Mercury Laboratories posts 53.7% profit jump to ₹4.83 crore, recommends 35% dividend

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorRiya Kapoor|Published at:
Mercury Laboratories posts 53.7% profit jump to ₹4.83 crore, recommends 35% dividend
Overview

Mercury Laboratories reported a 53.7% increase in net profit for FY26, reaching ₹4.83 crore from ₹3.14 crore in FY25. The company recommended a 35% dividend, alongside a corrigendum for minor reporting errors.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Mercury Laboratories Reports Strong Profit Growth and Dividend Recommendation

Mercury Laboratories reported a significant 53.71% increase in Net Profit After Tax for the financial year ended March 31, 2026, reaching ₹4.834 crore (₹483.40 lakh), up from ₹3.1449 crore (₹314.49 lakh) in the previous year.

Reader Takeaway: Profit growth is strong, but reporting errors require scrutiny.

What just happened

Mercury Laboratories announced its audited financial results for the fiscal year 2026. The company posted a net profit of ₹4.834 crore, marking a substantial increase from ₹3.1449 crore in FY25. Revenue from operations saw a modest increase of 1.11% to ₹75.9367 crore.

The Board of Directors has recommended a final dividend of 35%, equivalent to ₹3.50 per share, subject to shareholder approval.

Additionally, the company filed a corrigendum to its audited financial results. This corrigendum addressed a typographical error in the Balance Sheet concerning current liabilities and corrected an omission in the Cash Flow from Financing Activities.

Why this matters

The strong profit growth indicates improved operational efficiency or favourable market conditions for Mercury Laboratories. The dividend payout offers a direct financial benefit to shareholders. However, the need for a corrigendum highlights potential weaknesses in internal financial reporting controls, which investors should monitor.

The backstory

For the year ended March 2025, Mercury Laboratories had reported a Net Profit After Tax of ₹3.1449 crore and Revenue from Operations of ₹75.1012 crore. The company's performance has shown an upward trend in profitability.

What changes now

Shareholders can anticipate a dividend payout if approved. The corrigendum, while addressing minor errors, underscores the importance of accurate and robust financial reporting. Investors will be looking for continued profit growth and improvements in reporting accuracy in future quarters.

Risks to watch

  • Financial Reporting Accuracy: The issuance of a corrigendum for both a balance sheet error and a cash flow omission points to a potential need for enhanced internal control and review processes. Investors should monitor future filings for any recurrence of such issues.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

  • FY26 Revenue from Operations: ₹75.9367 crore
  • FY26 Net Profit after Tax: ₹4.834 crore
  • FY25 Net Profit after Tax: ₹3.1449 crore
  • Dividend Recommendation: 35% (₹3.50 per share)

What to track next

Investors should track the company's future financial performance, particularly its ability to maintain profit growth and ensure the accuracy of its financial reporting. The upcoming Annual General Meeting (AGM) will be key for dividend approval.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.